Investigation into ADMA Biologics for Securities Violations

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: 3 days ago

0mins

ADMA-3.54%

Should l Buy ADMA?

Source: Globenewswire

Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, focusing on allegations that the reported 20% revenue growth in 2025 was a result of a channel stuffing scheme to mask declining demand.
Revenue Growth Concerns: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allowed the company to inflate revenue figures; without this scheme, it would have faced a 3% revenue decline in 2025.
Stock Price Plummet: This news caused ADMA's stock price to drop by 29% over two trading days, falling from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating significant market concerns regarding the company's financial health.
Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, highlighting their commitment to protecting shareholder rights and interests.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ADMA

About ADMA

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Three Stocks Added to Zacks Rank #5 (Strong Sell) List

7 hours agoNASDAQ.COM

ADMA Biologics: ADMA Biologics, Inc. has seen its current year earnings estimate revised downward by 12.5% over the last 60 days, indicating a decline in market confidence regarding its future profitability, which may pressure its stock price.
Aptiv Components: Aptiv PLC's current year earnings estimate has been cut by 24.1% in the past 60 days, highlighting increasing challenges in the automotive sector that could impact its market performance and investor confidence.
Astec Industries: Astec Industries, Inc. has experienced a nearly 4% downward revision in its current year earnings estimate over the last 60 days, reflecting weakness in the construction equipment market that may negatively affect its sales and profitability.
Impact of AI Revolution: While the AI revolution has already created many millionaires, the well-known stocks may not continue to deliver the biggest profits, prompting investors to focus on emerging companies to seize future growth opportunities.

Rosen Law Firm Investigates ADMA Biologics for Misleading Information

22 hours agoGlobenewswire

Securities Claims Investigation: Rosen Law Firm has announced an investigation into ADMA Biologics for potentially issuing materially misleading business information, which poses a risk of securities claims for shareholders.
Stock Price Impact: On March 24, 2026, ADMA Biologics' stock fell by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue growth, resulting in direct financial losses for investors.
Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery of investor losses, allowing affected shareholders to participate without any upfront costs, thus providing legal support opportunities.
Firm's Track Record: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in the securities litigation field.

ADMA Biologics Under Investigation for Securities Violations

3 days agoGlobenewswire

Investigation Launched: Lowey Dannenberg P.C. is investigating ADMA Biologics for potential violations of federal securities laws, raising serious concerns about the company's financial transparency and potentially undermining investor confidence.
Channel Stuffing Allegations: A report by Culper Research claims that in 2025, ADMA Biologics induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, allegedly inflating revenue and resulting in a real growth of -3% instead of the reported 20%.
Financial Impact: Had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have faced a 3% revenue decline in 2025, indicating significant discrepancies in financial reporting that could lead to investor losses exceeding $50,000.
Legal Consequences: This investigation could result in legal action against ADMA Biologics, further damaging its reputation and affecting stock prices, prompting investors to closely monitor developments to assess potential risks.